Cuprina (CUPR) said Monday it has signed an agreement to acquire the right to market medical maggots for use in debridement therapy to treat chronic wounds in the US.

The agreement was signed with Ronald Sherman, who holds a 2004 US Food and Drug Administration clearance to market Lucilia sericata maggots, giving Cuprina the right to manufacture, sell, use, and distribute the medical maggots and associated dressings for maggot debridement therapy, according to a statement.

Sherman will join the company as medical and scientific director in September, Cuprina said.

Cuprina also said it is updating a submission to the FDA to seek approval for the use of another species of medical maggots, Lucilia cuprina, and could receive marketing clearance within 90 business days.

Price: 7.55, Change: -0.02, Percent Change: -0.26